Paxlovid

COVID-19 continues to hit seniors with disproportionate severity. Experts say Paxlovid is an effective therapy that is being underprescribed for people 65 and older.

The drug is the most effective way to cut the risk of severe disease. It's heading to China now. Yet the drug is underused in some places. Why? And are there options if you're not a good candidate?

The government soon will stop paying for the covid drug that has proved to be the most effective at keeping patients alive and out of the hospital.

The treatments were highly popular earlier in the pandemic. One by one, they got knocked out by more convenient, less expensive treatment options, and new COVID variants.

For those at high risk, Pfizer's antiviral drug helps stave off severe COVID-19. Now research suggests it may also reduce their chances of long COVID.

The White House announced the initiative this week as part of President Joe Biden’s push to increase COVID vaccinations and treatments to slow a possible fall and winter surge.

Paxlovid has been highly effective at reducing the risks of hospitalization and death, but some patients report a "Paxlovid rebound," in which the disease returns.

Paxlovid has been shown to curb the worst effects of COVID-19 but it has to be started within five days of symptoms. Previously, only doctors could prescribe it.

The White House announced more steps to make the treatment more accessible across the U.S. as it projects COVID-19 infections will continue to spread over the summer travel season.

In the past several months, new treatments have emerged, which are most effective within the first five days of symptoms but patients may have a hard time knowing whether they qualify.